AU3333099A - Use of stimulated peripheral blood mononuclear cells for the treatment of brain-related diseases, disorders and damage - Google Patents

Use of stimulated peripheral blood mononuclear cells for the treatment of brain-related diseases, disorders and damage

Info

Publication number
AU3333099A
AU3333099A AU33330/99A AU3333099A AU3333099A AU 3333099 A AU3333099 A AU 3333099A AU 33330/99 A AU33330/99 A AU 33330/99A AU 3333099 A AU3333099 A AU 3333099A AU 3333099 A AU3333099 A AU 3333099A
Authority
AU
Australia
Prior art keywords
brain
damage
disorders
treatment
peripheral blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU33330/99A
Inventor
Rudolf Wank
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU3333099A publication Critical patent/AU3333099A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46432—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to the use of stimulated peripheral blood mononuclear cells (PBMC) for the treatment of brain-related diseases, disorders and damage, such as manic-depressive illness or manic-depressive psychosis, schizophrenia, depressive syndromes without endogenous cause, autism, disturbances of cerebral development during and after the embryonal stage, Downs syndrome, brain damage due to accidents or other causes, and Parkinson's disease. After activation of the PMBC the stimulated cells can possibly also be treated with gamma-interferon and/or alpha-interferon.
AU33330/99A 1998-04-01 1999-03-31 Use of stimulated peripheral blood mononuclear cells for the treatment of brain-related diseases, disorders and damage Abandoned AU3333099A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19814701 1998-04-01
DE19814701A DE19814701A1 (en) 1998-04-01 1998-04-01 Use of stimulated peripheral blood mononuclear cells for the treatment of diseases, disorders and damage associated with the brain
PCT/EP1999/002225 WO1999050393A2 (en) 1998-04-01 1999-03-31 Use of stimulated peripheral blood mononuclear cells for the treatment of brain-related diseases, disorders and damage

Publications (1)

Publication Number Publication Date
AU3333099A true AU3333099A (en) 1999-10-18

Family

ID=7863301

Family Applications (1)

Application Number Title Priority Date Filing Date
AU33330/99A Abandoned AU3333099A (en) 1998-04-01 1999-03-31 Use of stimulated peripheral blood mononuclear cells for the treatment of brain-related diseases, disorders and damage

Country Status (6)

Country Link
EP (1) EP1068299B1 (en)
JP (1) JP2002509942A (en)
AT (1) ATE347586T1 (en)
AU (1) AU3333099A (en)
DE (3) DE19814701A1 (en)
WO (1) WO1999050393A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10120505A1 (en) * 2001-04-26 2002-11-07 Rudolf Wank Use of stimulated peripheral blood mononuclear cells for the treatment of cancer
IL147138A0 (en) 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
DE102012011839B4 (en) 2012-06-14 2018-03-22 Norbert Müller Use of interferon-gamma in a method for the treatment of psychiatric disorders
WO2015185602A1 (en) * 2014-06-04 2015-12-10 Affiris Ag Treatment and prevention of parkinson's disease (pd)
CN111349600A (en) * 2020-03-27 2020-06-30 郑州鲲鹏健康科技有限公司 PBMC (peripheral blood mononuclear cell) in-vitro culture medium and preparation method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0346022B1 (en) * 1988-06-10 1996-02-14 United Biomedical, Inc. Peptide fragments of HIV
WO1991003250A1 (en) * 1989-08-31 1991-03-21 The United States Of America, Represented By The Secretary, United States Department Of Commerce A method for the treatment of dopaminergic neurodegenerative disorders
JPH07102131B2 (en) * 1991-07-15 1995-11-08 日本石油株式会社 Method for enhancing cytotoxicity of human lymphocytes against cancer cells
AU1524095A (en) * 1994-01-27 1995-08-15 Cellcor, Inc. Ex vivo activation of immune cells
US5958416A (en) * 1994-12-16 1999-09-28 Regents Of The University Of Minnesota Heat shock protein peptides and methods for modulating autoimmune central nervous system disease

Also Published As

Publication number Publication date
DE19980543D2 (en) 2001-07-12
EP1068299B1 (en) 2006-12-06
EP1068299A2 (en) 2001-01-17
WO1999050393A2 (en) 1999-10-07
DE19814701A1 (en) 1999-10-07
ATE347586T1 (en) 2006-12-15
DE59914037D1 (en) 2007-01-18
JP2002509942A (en) 2002-04-02
WO1999050393A3 (en) 1999-11-18

Similar Documents

Publication Publication Date Title
KR100521829B1 (en) Compositions and Methods for the Treatment of Alzheimer's Disease, Central Nervous System Injury, and Inflammatory Diseases
ES8602768A1 (en) Novel N-(bicyclic heterocyclyl)-4-piperidinamines.
DE3579113D1 (en) COMPOSITIONS FOR THE REDUCTION, TREATMENT AND DETERMINATION OF ARTHRIC DISEASES AND SIMILAR CONDITIONS.
GB2364059A (en) Beta-Secretase enzyme compositions and methods
MY125142A (en) Arylsulphonamides and analogues
DE69935133D1 (en) ANTAGONIST FOR THE TREATMENT OF CD11 / CD18 ADHESION RECEPTOR-MEDIATED DISEASES
HU229448B1 (en) Multicyclic compounds and pharmaceutical compositions containing them
ATE307592T1 (en) EPIALLOPREGNANOLONE FOR THE TREATMENT OF CNS DISEASES
HK1077508A1 (en) 1-Alpha-hydroxy-2-methylene-19-nor-pregnacal ciferol and its uses
DE60105035D1 (en) 1ALPHA-HYDROXY-2-METHYLENE-19-NOR-HOMOPREGNACALCIFEROL AND ITS THERAPEUTIC USE
ES2063060T3 (en) BENZAMIDE AGAINST COGNOSCITIVE DISEASES.
NZ333232A (en) Use of p-aminophenol derivatives (paracetamol) to treat neurodegenerative disease
AU3333099A (en) Use of stimulated peripheral blood mononuclear cells for the treatment of brain-related diseases, disorders and damage
HUP0102456A2 (en) The use of valproic acid analog for the treatment and prevention of migraine and affective illness
BR9914848A (en) Composition and process for the treatment of disorders of the external retina
ATE271861T1 (en) USE OF NMDA ANTAGONISTS AND/OR SODIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES
CA2468833A1 (en) (20s)-1.alpha.-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
ATE118350T1 (en) COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES AND ACTIVATE WOUND HEALING.
HK1091657A1 (en) Use of pyrazolopyridines for the treatment of cognitive deficits
EA200200063A1 (en) IL6RIL6 CHEMISTRY FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
HUP0000785A3 (en) Ointment for the treatment of burns and other skin diseases
DE69418931D1 (en) Use of VIP and its analogs and fragments for the treatment of neurodegenerative diseases
IE811612L (en) Thiazoles
DE3769497D1 (en) AGENT FOR CONTROLLING PHYTOPATHOGENIC MICROBES.
AU603375B2 (en) Therapeutic agent for the treatment of disorders associated with cerebral ischemia

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase